Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.86
+14.8%
$1.67
$1.30
$8.01
$68.21M1.381.85 million shs11.66 million shs
PolyPid Ltd. stock logo
PYPD
PolyPid
$3.45
+0.6%
$3.50
$2.30
$3.93
$54.86M1.476,898 shs62,483 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$3.35
-2.6%
$4.69
$3.03
$9.33
$55.07M1.34244,865 shs72,653 shs
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$2.17
$2.16
$0.70
$3.44
$13.58M-1.11N/A51,531 shs
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%+31.91%+33.81%-10.14%-76.25%
PolyPid Ltd. stock logo
PYPD
PolyPid
0.00%+7.14%-4.70%+22.78%-8.00%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
0.00%-3.18%-22.81%-29.18%-48.30%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
0.00%0.00%0.00%0.00%+0.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
4.217 of 5 stars
3.34.00.04.42.40.01.3
PolyPid Ltd. stock logo
PYPD
PolyPid
2.8468 of 5 stars
3.65.00.00.01.81.70.0
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
2.0794 of 5 stars
3.51.00.00.02.11.70.6
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.60
Moderate Buy$8.80373.12% Upside
PolyPid Ltd. stock logo
PYPD
PolyPid
3.17
Buy$12.40259.42% Upside
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.00
Buy$8.00138.81% Upside
Vapotherm, Inc. stock logo
VAPO
Vapotherm
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VAPO, INO, SRTS, and PYPD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
PolyPid Ltd. stock logo
PYPD
PolyPid
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $13.00
8/14/2025
PolyPid Ltd. stock logo
PYPD
PolyPid
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00
8/13/2025
PolyPid Ltd. stock logo
PYPD
PolyPid
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
8/12/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $8.00
8/8/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $6.00
7/9/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$5.00
6/18/2025
PolyPid Ltd. stock logo
PYPD
PolyPid
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$12.00 ➝ $9.00
6/17/2025
PolyPid Ltd. stock logo
PYPD
PolyPid
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $14.00
6/9/2025
PolyPid Ltd. stock logo
PYPD
PolyPid
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$11.00 ➝ $13.00
6/5/2025
PolyPid Ltd. stock logo
PYPD
PolyPid
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$220K310.03N/AN/A$1.90 per share0.98
PolyPid Ltd. stock logo
PYPD
PolyPid
N/AN/AN/AN/A$0.75 per shareN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$41.81M1.32$0.43 per share7.76$3.41 per share0.98
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$68.67M0.20N/AN/A($9.01) per share-0.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$107.25M-$2.61N/AN/AN/AN/A-163.32%-96.41%N/A
PolyPid Ltd. stock logo
PYPD
PolyPid
-$29.02M-$3.83N/AN/AN/A-453.95%-138.92%N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$6.65M-$0.06N/A14.57N/A-2.26%-1.58%-1.41%N/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
-$58.19M-$8.51N/AN/A-76.74%N/A-68.08%N/A

Latest VAPO, INO, SRTS, and PYPD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
PolyPid Ltd. stock logo
PYPD
PolyPid
-$0.53-$0.78-$0.25-$0.78N/AN/A
8/12/2025Q2 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.63-$0.61+$0.02-$0.61$0.01 millionN/A
8/7/2025Q2 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.01-$0.06-$0.07-$0.06$9.30 million$7.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
PolyPid Ltd. stock logo
PYPD
PolyPid
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
1.66
1.66
PolyPid Ltd. stock logo
PYPD
PolyPid
N/A
2.28
2.28
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
8.14
5.79
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A
0.25
0.09

Institutional Ownership

CompanyInstitutional Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
PolyPid Ltd. stock logo
PYPD
PolyPid
26.47%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
43.08%

Insider Ownership

CompanyInsider Ownership
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
PolyPid Ltd. stock logo
PYPD
PolyPid
24.70%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
8.90%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
15.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million35.83 millionOptionable
PolyPid Ltd. stock logo
PYPD
PolyPid
8015.90 million11.97 millionNo Data
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
4016.44 million14.98 millionOptionable
Vapotherm, Inc. stock logo
VAPO
Vapotherm
2906.26 million5.27 millionNo Data

Recent News About These Companies

Vapotherm, Inc.: Vapotherm Announces Closing of Merger
Vapotherm Announces Closing of Merger
PLPL Plandaí Biotechnology, Inc.
VA20.SG,0P0001F4D7,0 (VA20.SG)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.86 +0.24 (+14.81%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$1.86 +0.00 (+0.27%)
As of 06:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

PolyPid stock logo

PolyPid NASDAQ:PYPD

$3.45 +0.02 (+0.58%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$3.44 -0.02 (-0.43%)
As of 08/15/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Sensus Healthcare stock logo

Sensus Healthcare NASDAQ:SRTS

$3.35 -0.09 (-2.62%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$3.34 0.00 (-0.15%)
As of 04:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

Vapotherm stock logo

Vapotherm NYSE:VAPO

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.